|
ES2688035T3
(es)
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
|
US11091546B2
(en)
*
|
2015-04-15 |
2021-08-17 |
The Scripps Research Institute |
Optimized PNE-based chimeric receptor T cell switches and uses thereof
|
|
EP3735425A1
(en)
|
2018-01-04 |
2020-11-11 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor specific for bdca2 antigen
|
|
WO2019152957A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Dna-chimeric antigen receptor t cells for immunotherapy
|
|
JP7394067B2
(ja)
*
|
2018-04-04 |
2023-12-07 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がん患者における腫瘍抗原を検出するための診断アッセイ
|
|
EP3773594A4
(en)
*
|
2018-04-05 |
2021-12-29 |
Mayo Foundation for Medical Education and Research |
Materials and methods for treating cancer
|
|
BR112020020246A8
(pt)
|
2018-04-05 |
2022-10-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de cinase axl e uso dos mesmos
|
|
WO2019222642A1
(en)
*
|
2018-05-18 |
2019-11-21 |
Senti Biosciences, Inc. |
Engineered immune cells and methods of use
|
|
CN112930186A
(zh)
*
|
2018-08-16 |
2021-06-08 |
纪念斯隆-凯特琳癌症中心 |
基于亮氨酸拉链的组合物和使用方法
|
|
CA3112212A1
(en)
*
|
2018-10-03 |
2020-04-09 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
|
|
WO2020092736A1
(en)
|
2018-10-31 |
2020-05-07 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
WO2020092839A1
(en)
|
2018-10-31 |
2020-05-07 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
CN119752797A
(zh)
*
|
2019-01-22 |
2025-04-04 |
北京大学深圳研究生院 |
天然配体介导的多靶点识别可调控基因工程化免疫细胞的制备方法
|
|
CA3124444A1
(en)
|
2019-01-23 |
2020-07-30 |
Miltenyi Biotec B.V. & Co. KG |
A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
|
|
WO2020201527A1
(en)
|
2019-04-04 |
2020-10-08 |
Umc Utrecht Holding B.V. |
Modified immune receptor constructs
|
|
CN110151999A
(zh)
*
|
2019-05-22 |
2019-08-23 |
中国人民解放军第四军医大学 |
用于抑制恶性黑色素瘤进展的靶向药物
|
|
EP3976763A1
(en)
|
2019-05-28 |
2022-04-06 |
Miltenyi Biotec B.V. & Co. KG |
Method for generation of genetically modified t cells
|
|
WO2021007580A1
(en)
|
2019-07-11 |
2021-01-14 |
Valkyr, Inc. |
System and methods relating to chimeric autoantibody receptors
|
|
EP4028049A1
(en)
|
2019-09-11 |
2022-07-20 |
Miltenyi Biotec B.V. & Co. KG |
In vitro method for transduction of t cells in the presence of malignant cells
|
|
US11723950B2
(en)
|
2019-10-18 |
2023-08-15 |
Trustees Of Boston University |
CAL-T constructs and uses thereof
|
|
WO2021119489A1
(en)
|
2019-12-11 |
2021-06-17 |
A2 Biotherapeutics, Inc. |
Lilrb1-based chimeric antigen receptor
|
|
TW202128131A
(zh)
*
|
2020-01-17 |
2021-08-01 |
大陸商信達生物制藥(蘇州)有限公司 |
重組抗程式性細胞死亡受體1和抗分化抗原簇137雙特異性抗體製劑及其用途
|
|
CN111234033B
(zh)
*
|
2020-01-21 |
2021-05-11 |
南京北恒生物科技有限公司 |
多链嵌合抗原受体及其用途
|
|
EP4100027A1
(en)
|
2020-02-04 |
2022-12-14 |
Miltenyi Biotec B.V. & Co. KG |
Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
|
|
JP2023515055A
(ja)
*
|
2020-02-20 |
2023-04-12 |
センティ バイオサイエンシズ インコーポレイテッド |
阻害性キメラ受容体アーキテクチャ
|
|
TW202146436A
(zh)
*
|
2020-02-20 |
2021-12-16 |
美商聖堤生物科技股份有限公司 |
抑制性嵌合受體架構
|
|
AU2021237570A1
(en)
|
2020-03-16 |
2022-09-08 |
Angeles Therapeutics, Inc. |
Novel antigen binding domains and synthetic antigen receptors incorporating the same
|
|
WO2021191871A1
(en)
*
|
2020-03-27 |
2021-09-30 |
Dcprime B.V. |
In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
WO2021226289A2
(en)
*
|
2020-05-05 |
2021-11-11 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
|
|
WO2021234006A1
(en)
|
2020-05-20 |
2021-11-25 |
Miltenyi Biotec B.V. & Co. KG |
Compositions and methods for treating cancer expressing cd90 and cd326
|
|
EP3915578A1
(en)
|
2020-05-28 |
2021-12-01 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor with a spacer comprising c2-set ig-like domains
|
|
EP4171617A1
(en)
|
2020-06-30 |
2023-05-03 |
Mendus B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
EP4200325A1
(en)
|
2020-08-19 |
2023-06-28 |
Astellas Pharma Inc. |
Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor
|
|
EP4100028A4
(en)
|
2020-08-20 |
2023-07-26 |
A2 Biotherapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATMENT OF MESOTHELIN-POSITIVE CARCINOMAS
|
|
ES2984902T3
(es)
|
2020-08-20 |
2024-10-31 |
A2 Biotherapeutics Inc |
Composiciones y métodos para tratar cánceres positivos para EGFR
|
|
MX2023002017A
(es)
|
2020-08-20 |
2023-04-28 |
A2 Biotherapeutics Inc |
Composiciones y métodos para tratar cánceres positivos para ceacam.
|
|
WO2022049217A1
(en)
|
2020-09-04 |
2022-03-10 |
Miltenyi Biotec B.V. & Co. KG |
System for inducible expression of an adapter in immune cells
|
|
WO2022081841A1
(en)
*
|
2020-10-16 |
2022-04-21 |
Fred Hutchinson Cancer Research Center |
Specific targeting of tumor-infiltrating regulatory t cells (tregs) using icos and il-1r1
|
|
US20230405047A1
(en)
|
2020-11-09 |
2023-12-21 |
Miltenyi Biotec B.V. & Co. KG |
Methods and compositions for eliminating engineered immune cells
|
|
KR20230135075A
(ko)
|
2021-01-22 |
2023-09-22 |
멘두스 비.브이. |
종양 백신접종 방법
|
|
WO2023057285A1
(en)
|
2021-10-06 |
2023-04-13 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
US11819578B2
(en)
|
2021-10-07 |
2023-11-21 |
Trustees Of Boston University |
Nanofiber scaffolds
|
|
WO2023062113A1
(en)
|
2021-10-15 |
2023-04-20 |
Miltenyi Biotec B.V. & Co. KG |
Method for the generation of genetically modified nk cells
|
|
WO2023187031A1
(en)
|
2022-04-01 |
2023-10-05 |
Miltenyi Biotec B.V. & Co. KG |
A system for drug-inducible expression of a polynucleotide
|
|
US20250295773A1
(en)
|
2022-05-10 |
2025-09-25 |
Miltenyi Biotec B.V. & Co. KG |
Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy
|
|
WO2023222617A1
(en)
|
2022-05-16 |
2023-11-23 |
Miltenyi Biotec B.V. & Co. KG |
Endogenous signaling molecule activating chimeric antigen receptors and methods of generation thereof
|
|
EP4342488A1
(en)
|
2022-09-26 |
2024-03-27 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor specific for folate receptor 1
|
|
EP4602171A1
(en)
|
2022-10-15 |
2025-08-20 |
Miltenyi Biotec B.V. & Co. KG |
Transduction of gammadelta t cells with pseudotyped retroviral vectors
|
|
WO2024108109A1
(en)
|
2022-11-18 |
2024-05-23 |
Trustees Of Boston University |
Self-replicating rna and uses thereof
|
|
EP4471067A1
(en)
|
2023-06-01 |
2024-12-04 |
Miltenyi Biotec B.V. & Co. KG |
A chemically inducible heterodimerizing system and a method for generation thereof
|
|
WO2025008108A1
(en)
|
2023-07-06 |
2025-01-09 |
Miltenyi Biotec B.V. & Co. KG |
Immune cell expressing chimeric antigen receptor and transgenic t cell receptor
|
|
EP4545963A1
(en)
|
2023-10-26 |
2025-04-30 |
Miltenyi Biotec B.V. & Co. KG |
Method for selecting antigen recognizing moieties having specificity for a target structure
|
|
WO2025224123A1
(en)
|
2024-04-25 |
2025-10-30 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptors specific for fibroblast activation protein
|
|
WO2025252326A1
(en)
|
2024-06-06 |
2025-12-11 |
Miltenyi Biotec B.V. & Co. KG |
A human protein scaffold library based on the n-terminal domain of human fact complex subunit ssrp1
|
|
WO2025252325A1
(en)
|
2024-06-06 |
2025-12-11 |
Miltenyi Biotec B.V. & Co. KG |
A human protein scaffold library based on the pdz3 domain of the tight junction protein zo-1
|